Login to Your Account

Spinraza 'sprinting out of the gates' to drive Biogen's first-quarter revenues

By Marie Powers
News Editor

Tuesday, April 25, 2017

Cowen and Co. analyst Eric Schmidt summed up the sentiment of analysts on Biogen Inc.'s first-quarter financials, headlining a note on the company's "solid" performance with the observation that the SMA drug Spinraza was "sprinting out of the gates."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription